Sjögren’s syndrome (SS) is an autoimmune connective tissue disease affecting the body’s moisture-producing glands. Some studies have linked SS to adverse maternal/neonatal outcomes, but sample sizes have tended to be small, with few outcomes examined. The purpose of this study was to evaluate the effect of SS on pregnancy outcomes for mother and neonate using a large dataset.
We carried out a retrospective cohort study of women who delivered between 1999 and 2014 using data from the Nationwide Inpatient Sample from the United States. SS categorization is based on ICD-9 coding. Baseline characteristics were compared in both groups and multivariate logistic regression was used to compare maternal and fetal outcomes of pregnancies in women with and without SS.
The prevalence of SS in our population was 1.34 cases/10,000 births, with the rate increasing over the study period. Women with SS tended to be older, Caucasian and to have pre-existing comorbidities. Births to women with SS were at greater risk of pre-eclampsia [odds ratio (OR) 1.63, 95% confidence interval (CI) 1.34–1.99]; premature rupture of membranes (OR 1.28, 95% CI 1.04–1.57); preterm delivery (OR 1.56, 95% CI 1.34–1.81); cesarean delivery (OR 1.29, 95% CI 1.17–1.41); and venous thromboembolic events (OR 3.71, 95% CI 2.57–5.35). Infants of women with SS were more likely to have intrauterine growth restriction (IUGR) (OR 3.00, 95% CI 2.46–3.65); and congenital malformations (OR 3.26, 95% CI 2.30–4.62).
SS is a high-risk pregnancy condition associated with significant comorbidities and adverse maternal and fetal outcomes. Women with SS may benefit from increased surveillance during their pregnancies.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. Immunopathogenesis of Sjogren’s syndrome. Clin Rev Allergy Immunol 2003;25:89–104.10.1385/CRIAI:25:1:89Search in Google Scholar
2. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006;45(Suppl 3):iii3–4.10.1093/rheumatology/kel282Search in Google Scholar
3. Mavragani CP, Nezos A, Moutsopoulos HM. New advances in the classification, pathogenesis and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 2013;25:623–9.10.1097/BOR.0b013e328363eaa5Search in Google Scholar
4. Upala S, Yong WC, Sanguankeo A. Association between primary Sjögren’s syndrome and pregnancy complications: a systematic review and meta-analysis. Clin Rheumatol 2016;35:1949–55.10.1007/s10067-016-3323-9Search in Google Scholar
5. Agency for Healthcare Research and Quality. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2017 [updated April 2017, November 12 2017]. Available from: http://www.hcup-us.ahrq.gov/databases.jsp.Search in Google Scholar
6. Koch T, Al-Hashimi I, Koffman BM, Deshpande A, Khuder SA. Comorbidities associated with Sjögren’s syndrome: results from the Nationwide Inpatient Sample. Translation: Univ Toledo J Med Sci 2014;1:4–7.10.46570/utjms.vol1-2014-74Search in Google Scholar
7. Patel R, Shahane A. The epidemiology of Sjogren’s syndrome. Clin Epidemiol 2014;6:247–55.10.2147/CLEP.S47399Search in Google Scholar
8. Hussein SZ, Jacobsson LT, Lindquist PG, Theander E. Pregnancy and fetal outcome in women with primary Sjögren’s syndrome compared with women in the general population: a nested case-control study. Rheumatology 2011;50:1612–7.10.1093/rheumatology/ker077Search in Google Scholar
9. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.10.1136/ard.61.6.554Search in Google Scholar
10. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008;87:210–9.10.1097/MD.0b013e318181e6afSearch in Google Scholar
11. Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002;81:270–80.10.1097/00005792-200207000-00003Search in Google Scholar
12. De Carolis S, Salvi S, Botta A, Garofalo S, Garufi C, Ferrazzani S, et al. The impact of primary Sjogren’s syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev 2014;13:103–7.10.1016/j.autrev.2013.09.003Search in Google Scholar
13. Ballester C, Grobost V, Roblot P, Pourrat O, Pierre F, Laurichesse-Delmas H, et al. Pregnancy and primary Sjögren’s syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies. Scand J Rheumatol 2017;46:56–63.10.3109/03009742.2016.1158312Search in Google Scholar
14. Julkunen H, Kaaja R, Kurki P, Palosuo T, Friman C. Fetal outcome in women with primary Sjögren’s syndrome. A retrospective case-control study. Clin Exp Rheumatol 1995;13:65–71.Search in Google Scholar
15. Bleau N, Patenaude V, Abenhaim HA. Risk of venous thromboembolic events in pregnant patients with autoimmune diseases: a population-based study. Clin Appl Thromb Hemost 2016;22:285–91.10.1177/1076029614553023Search in Google Scholar
16. Morel N, Georgin-Lavialle S, Levesque K, Guettrot-ImbertG, Le Guern V, Le Bidois J, et al. [Neonatal lupus syndrome: Literature review]. Rev Med Intern 2015;36:159–66.10.1016/j.revmed.2014.07.013Search in Google Scholar
17. Lehrer S, Bogursky E, Yemini M, Kase NG, Birkenfeld A. Gynecologic manifestations of Sjögren’s syndrome. Am J Obstet Gynecol 1994;170:835–7.10.1016/S0002-9378(94)70294-2Search in Google Scholar
18. Carvalheiras G, Faria R, Braga J, Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmun Rev 2012;11:A520–30.10.1016/j.autrev.2011.12.002Search in Google Scholar PubMed
19. Spinillo A, Beneventi F, Ramoni V, Caporali R, Locatelli E, Simonetta M, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann Rheumat Dis 2012;71:918–23.10.1136/annrheumdis-2011-154146Search in Google Scholar PubMed
20. Spinillo A, Beneventi F, Locatelli E, Ramoni V, Caporali R, AlpiniC, et al. The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study. BMC Preg Childbirth 2016;16:313.10.1186/s12884-016-1076-8Search in Google Scholar PubMed PubMed Central
21. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:127.e1–6.10.1016/j.ajog.2008.03.012Search in Google Scholar PubMed PubMed Central
22. Magtanong GG, Spence AR, Czuzoj-Shulman N, Abenhaim HA. Maternal and neonatal outcomes among pregnant women with fibromyalgia: a population-based study of 12 million births. J Matern Fetal Neonatal Med 2019;32:404–10.10.1080/14767058.2017.1381684Search in Google Scholar PubMed
© 2019 Walter de Gruyter GmbH, Berlin/Boston